Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of two synthetic corticosteroids, dexamethasone and triamcinolone acetonide. Both are potent anti-inflammatory and immunosuppressive agents used to treat a wide range of inflammatory, allergic, autoimmune, and some neoplastic conditions. Dexamethasone is known for its high glucocorticoid potency and long duration of action. Triamcinolone acetonide is a more potent derivative of triamcinolone with enhanced topical activity and reduced mineralocorticoid effect; it is commonly used in injectable, topical, nasal spray, or intravitreal forms for various indications including joint inflammation, skin disorders, allergic rhinitis, macular edema associated with uveitis or diabetic macular edema (DME), among others[3][6][8]. The combination may be considered in clinical scenarios where additive or synergistic anti-inflammatory effects are desired. However, studies suggest that combining these corticosteroids (or either one) with other agents such as anti-VEGF drugs does not necessarily improve efficacy but increases the risk of side effects like elevated intraocular pressure[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dexamethasone + triamcinolone acetonide.